作者:Christian M. König、Björn Gebhardt、Cornelia Schleth、Mario Dauber、Ulrich Koert
DOI:10.1021/ol900757k
日期:2009.7.2
convergent total synthesis of the PP2A-inhibitor phoslactomycin A was achieved using a CuTC-mediated coupling of an alkenyl iodide C1−C13fragment with an C14−C21 alkenyl stannane in the presence of a protected phosphate. Key features for the assembly of the C1−C13fragment were an asymmetric dihydroxylation, an Evans−Aldol reaction, and a well-balanced protective group strategy. An asymmetric 1,4-addition
Good Timing in Total Synthesis: The Case of Phoslactomycin A
作者:Björn Gebhardt、Christian M. König、Cornelia Schleth、Mario Dauber、Ulrich Koert
DOI:10.1002/chem.201000104
日期:2010.5.25
functional group introduction and manipulation (good timing) was demonstrated in the course of a totalsynthesis of phoslactomycin A. The synthetic strategy comprised a CuI–thiophene carboxylate (CuTC, Liebeskind’s reagent)‐mediated coupling to introduce the Z,Z‐diene at the final stage of the synthesis in the presence of a protected phosphate. Key features for the assembly of the C1–C13 fragment were
The invention is novel intermediates useful in producing taxol. These include the oxazolidine ester (III) ##STR1## the oxazolidine acid (IV) ##STR2## and the oxazolidine (XI) ##STR3##
1,3-Dioxolanone alcohols, prepared via the addition of chiral lithiumenolates of 1,3-dioxolan-4-ones to aldehydes, are suitable intermediates for the synthesis of chiral trisubstituted isoserines or trisubstituted 3-hydroxy-β-lactams. In particular, the methyl ester of 2-methyl-3-(2-furyl)isoserinic acid and two 3-methyl-3-hydroxy-β-lactams bearing either a 2-furyl or a phenyl substituent at C-(4)
[EN] A SEMI-SYNTHETIC PROCESS FOR THE PREPARATION OF N DEBENZOYLPACLITAXEL<br/>[FR] PROCEDE SEMI-SYNTHETIQUE DE PREPARATION DE N- DEBENZOYLPACLITAXEL
申请人:INDENA SPA
公开号:WO2003087077A1
公开(公告)日:2003-10-23
A process for the preparation of N-debenzoylpaclitaxel (I) through esterification of 7-protected baccatin III with a carboxylic acid reactive derivative of general formula (II), and elimination of the ester-protecting groups in acid conditions and in a single step. In formula (II) R1 is aryl or heteroaryl. The compound of formula (I) can be conveniently used for the preparation of paclitaxel and analogues.